An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | MicrobiomeTrials
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-03-11Est. Completion: 2028-04-12
Enrollment target: 40 participants
Locations
Ja0005 50646, Calgary, Canada
Ja0005 50644, Montreal, Canada
Ja0005 50645, Saskatoon, Canada
Ja0005 40777, Indre-et-Loire, France
Ja0005 40510, Le Kremlin-Bicêtre, France
Ja0005 40778, Paris, France
Ja0005 40776, Poitiers, France
Ja0005 40369, Berlin, Germany
Ja0005 40356, Dresden, Germany
Ja0005 40072, Freiburg im Breisgau, Germany
Ja0005 40852, Hamburg, Germany
Ja0005 40787, Sankt Augustin, Germany
Ja0005 40779, Sendenhorst, Germany
Ja0005 40427, Tübingen, Germany
Ja0005 40720, Krakow, Poland
Ja0005 40780, Sosnowiec, Poland
Ja0005 40781, Esplugues de Llobregat, Spain
Ja0005 40100, Madrid, Spain
Ja0005 40782, Valencia, Spain
Ja0005 40786, Bristol, United Kingdom
Ja0005 40783, Manchester, United Kingdom
Ja0005 40785, Nottingham, United Kingdom
Other microbiome trials you might be interested in